Skip to main content
. 2022 Jan 7;24:e1. doi: 10.1017/erm.2021.28

Fig. 3.

Fig. 3.

Comparative effects of CYP2D6 phenotype of hetEMs/IMs/PMs versus EMs on disease-free survival (DFS). hetEMs, heterozygotype-extensive metabolisers; IMs, intermediate metabolisers; PMs, poor metabolisers; EMs, extensive metaboliser.